1. Introduction {#sec1}
===============

The blood--brain barrier (BBB) separates the parenchyma of the central nervous system from the blood. Quantitative information about the functional integrity of the BBB can be gained by performing dynamic contrast-enhanced MRI (DCE-MRI). DCE-MRI has proven valuable in the assessment of many brain pathologies that cause an opening of the BBB, such as tumors ([@bb0075]), multiple sclerosis ([@bb0041]) and acute ischemic strokes ([@bb0044]). While these diseases show relatively large abnormalities in BBB functionality, there is also growing interest in the application of DCE-MRI to pathologies associated with more subtle and chronic BBB disruption, such as cerebral small vessel disease ([@bb0096]; [@bb0095]), diabetes ([@bb0082]) and Alzheimer\'s disease ([@bb0081]).

Although DCE-MRI has been widely used to study pathological changes in BBB functionality, studies differ in their MR imaging procedures and have been performed using a variety of different MRI sequences, contrast agents and time courses. Furthermore, there is no standard method for analyzing the data. Established analysis approaches include relatively simple non-model based methods ([@bb0091]) as well as a range of pharmacokinetic models ([@bb0090]). Several previous reviews have focused on specific applications such as oncology ([@bb0092]; [@bb0040]; [@bb0010]) and on methodological aspects of DCE-MRI ([@bb0080; @bb0085]); as far as we are aware, there are no reviews that cover the application of DCE-MRI in aging, microvascular disease or dementia. The aim of this work is to provide an overview of all applications and scanning protocols used in DCE-MRI of the brain by performing a systematic review of the literature. First, we describe the important components of the BBB and available permeability models, then review available data on BBB permeability imaging. Furthermore, we aim to identify the most commonly used methods for data analysis and provide an overview of the resulting parameter ranges.

2. Background {#sec2}
=============

2.1. Blood--brain barrier functionality {#sec2.1}
---------------------------------------

The BBB is formed by endothelial cells that line brain capillaries and are sealed by tight junctions, which are unique to the brain microvasculature. The endothelium of the BBB interacts with several cellular and non-cellular elements, such as astrocytes, pericytes, microglial cells and basement membranes, that provide both functional support and structural support to the BBB ([@bb001]; [@bb0066]). Together they form an interactive cellular complex, the 'neurovascular unit' (NVU). A schematic drawing of the NVU is shown in [Fig. 1](#f0005){ref-type="fig"}. The BBB regulates the passage of essential molecules such as glucose, while restricting the diffusion of potentially harmful substances.

Many brain pathologies are known to cause a disruption of the BBB. The mechanisms that cause BBB opening are many and differ between diseases. In meningitis, for example, damage to the BBB is initiated by extrinsic systemic factors, such as infections and autoimmune processes. Other diseases, including Alzheimer\'s disease and ischemic stroke, are thought to activate intrinsic cellular mechanisms secondary to the neuroinflammatory injury and other as yet unknown processes ([@bb0071]). Several comprehensive reviews provide detailed information on the molecular biology of BBB disruption in disease ([@bb001]; [@bb0066]; [@bb0071]).

2.2. Measurement of blood--brain barrier disruption using DCE-MRI {#sec2.2}
-----------------------------------------------------------------

Disruption of the BBB can enable the extravasation of low-molecular weight MRI contrast agents. This accumulation of contrast material in the extravascular extracellular space (EES) of affected tissues leads to increased longitudinal relaxation rate and, therefore, increased signal intensity in T1-weighted images. DCE-MRI exploits this T1 enhancement in order to detect and evaluate regions of BBB disruption. The DCE-MRI procedure typically consists of intravenous injection of contrast agent followed by the repeated acquisition of T1-weighted images (see [Fig. 2](#f0010){ref-type="fig"}), providing measurements of signal enhancement as a function of time. The enhancement kinetics can be used to extract quantitative or semi-quantitative information regarding BBB integrity.

MR signal changes caused by contrast agent extravasation are determined by several factors, including tissue perfusion and capillary permeability. In the brain, DCE-MRI is considered to be the standard MRI approach for assessing permeability, while dynamic susceptibility contrast MRI (DSC-MRI) is the method of choice for perfusion imaging ([@bb0078]). However, it has been shown that DCE-MRI can combine perfusion and permeability measurements by using a sufficiently long acquisition time (to capture slow interstitial uptake) with high temporal resolution early on (to capture the first pass of the contrast bolus) ([@bb0055]; [@bb0054]; [@bb0077]; [@bb0050]).

2.3. Analysis of DCE-MRI data {#sec2.3}
-----------------------------

Different approaches have been used to analyze DCE-MRI data, ranging from relatively simple visual assessment of enhancement curves to more complex fitting to pharmacokinetic models. Heuristic analysis of the signal enhancement curves provides semi-quantitative measures of BBB disruption, such as the area under the curve (AUC) and the time to maximum enhancement. Such measurements are easy to obtain but difficult to interpret ([@bb0014]). Quantitative analysis on the other hand aims to provide a link between the tissue signal enhancement and physiologically relevant parameters such as microvascular permeability, blood flow, blood volume fraction and interstitial volume fraction.

In order to relate the measured signal enhancement to the contrast agent concentration, an appropriate signal model is required. While early DCE-MRI studies assumed a linear relationship between signal enhancement and contrast uptake, it is well known that the signal enhancement is highly dependent on intrinsic tissue and acquisition parameters ([@bb005]; [@bb006]). Consequently, more complex approaches were developed in order to control for the effect of tissue characteristics such as the pre-contrast longitudinal relaxation time and the longitudinal and transverse relaxivities of the contrast agent ([@bb005]).

Pharmacokinetic modeling was first introduced for the analysis of DCE-MRI in the early 1990s by [@bb0012], [@bb0049], and [@bb0090], followed by a consensus paper on the notation ([@bb0089]). Since then, improvement of the imaging techniques (e.g. higher temporal resolution and contrast-to-noise ratio) and a better understanding of the underlying physiology have promoted the development of several more complex pharmacokinetic models. Detailed reviews of tracer kinetic modelling approaches in DCE-MRI have been published by [@bb0080; @bb0085]. In the following, we will briefly describe a basic tissue model and the three most commonly used pharmacokinetic models in DCE-MRI.

[Fig. 3](#f0015){ref-type="fig"}A displays a general tissue model with exchange of contrast agent between blood plasma and the EES. Target parameters of pharmacokinetic modeling in DCE-MRI are the fractional plasma volume *v~p~*, the fractional interstitial volume *v~e~*, the plasma flow *F~p~* and the permeability-surface area product *PS*, which measures the rate at which contrast agent particles leak out of the plasma and into the EES per unit tissue volume and plasma concentration. An important physiological parameter that is widely reported in DCE-MRI studies is the volume transfer constant *K*^Trans^, which is the rate at which contrast agent is delivered to the EES per volume of tissue and contrast agent concentration in the arterial blood plasma. While the terms *PS* and *K*^Trans^ are sometimes used interchangeably in the literature, *PS* represents the clearance for contrast agent leaking from the capillary plasma into the EES, i.e. the flux of contrast agent across the BBB normalized to the tissue plasma concentration and tissue volume; in contrast, *K*^Trans^ (as implicitly defined by [@bb0089], is the contrast clearance normalized to the *arterial* plasma concentration and therefore depends on the plasma flow *F*~*p*~ supplying the capillaries in addition to *PS* (the mathematical form of this relationship is model-dependent). *K*^Trans^ is necessarily equal to the product of plasma flow *F~p~* and the extraction fraction *E* (i.e. the fraction of contrast agent molecules that leak into the EES).

Most pharmacokinetic models require the arterial input function (AIF) to be known, which describes the tracer concentration in blood plasma over time. There are several strategies for determining the AIF ([@bb0015]), including the use of a standard function ([@bb0098]), experimentally derived population-averaged AIFs ([@bb0067]) and simultaneous individual measurement of the AIF in a feeding vessel close to the tissue of interest ([@bb0077]).

The conventional Tofts model ([@bb0090]) considers isodirectional flux of tracer between the two well-mixed blood plasma and EES compartments with the volume transfer constant *K*^Trans^. The plasma compartment is assumed to have negligible volume (*v~p~* ≈ 0), which makes the classic Tofts model a one-compartment model for weakly vascularized tissues. This model is illustrated in [Fig. 3B](#f0015){ref-type="fig"} and characterized by the working [Eq. (1)](#eqn1){ref-type="disp-formula"}:$$C_{t}\left( t \right) = K^{\text{Trans}}\int\limits_{0}^{t}C_{p}\left( \tau \right)\text{exp}\left\lbrack {- \frac{K^{\text{Trans}}\left( {t - \tau} \right)}{v_{e}}} \right\rbrack d\tau,$$

where *C~p~*(*t*) is the AIF.

Tofts et al. extended their classic model by introducing the blood plasma as a second well-mixed and highly perfused compartment ([@bb0089]; see [Fig. 3](#f0015){ref-type="fig"}C). In addition to the two parameters *K*^Trans^ and *v~e~*, the model allows the fractional plasma volume *v~p~* to be estimated and, hence, separates enhancement effects due to contrast leakage from those due to intravascular contrast:

$$C_{t}\left( t \right) = v_{p}C_{p}\left( t \right) + K^{\text{Trans}}\int\limits_{0}^{t}C_{p}\left( \tau \right)\text{exp}\left\lbrack {- \frac{K^{\text{Trans}}\left( {t - \tau} \right)}{v_{e}}} \right\rbrack d\tau.$$

If the model fits the data well with a non-negligible *v~p~* value, then the tissue must be highly perfused (*F~p~* = ∞) and the system is permeability-limited with *K*^Trans^ = *PS* ([@bb0078]).

Finally, the Patlak model also describes a highly perfused two-compartment tissue but considers unidirectional transport from the blood plasma into the EES (see [Fig. 3D](#f0015){ref-type="fig"}). The tracer concentration in tissue is given by$$C_{t}\left( t \right) = v_{p}C_{p}\left( t \right) + K^{\text{Trans}}\int\limits_{0}^{t}C_{p}\left( \tau \right)d\tau.$$

When first introducing this approach, Patlak and colleagues proposed a linear graphical analysis method, which is often used as it permits simple and fast fitting. In this analysis, the ratio *C~t~*(*t*)/*C~p~*(*t*) is regressed against $\int\limits_{0}^{t}C_{p}\left( \tau \right)d\tau/C_{p}\left( t \right)$, yielding a straight line with slope *K*^Trans^ and y-intercept *v*~p~.

3. Methods {#sec3}
==========

3.1. Search strategy {#sec3.1}
--------------------

The existing literature was systematically reviewed up to February 2014 by performing an electronic search in PubMed, EMBASE, MEDLINE and Web of Knowledge databases. Multiple combinations of the following search terms were used: 'permeability', 'brain', 'blood--brain barrier', 'MRI', 'dynamic', 'DCE-MRI' and 'contrast enhancement'. English as well as non-English literature was sought. The electronic search was supplemented by hand searching the reference lists of review papers.

One reviewer performed the primary literature search, removed duplicates and screened all papers\' titles and abstracts in order to identify those relevant for full assessment. Before final inclusion or exclusion of studies, a second reviewer continued the search, read the full text of the selected articles, extracted the relevant data and performed the analysis. Disagreements between reviewers about inclusion or exclusion of papers were resolved through discussion with a third reviewer. The third, fourth and fifth reviewers complemented the search and assisted with the data analysis.

3.2. Eligibility criteria {#sec3.2}
-------------------------

We sought studies which assessed BBB integrity using dynamic contrast-enhanced MRI techniques. We included studies on humans and animals in all diseases known or thought to affect BBB function. Consequently, we excluded other applications of DCE-MRI such as breast or prostate cancer as well as publications that focus on theoretical aspects of image processing or modeling without testing them in a clinical setting (e.g. [@bb0030]). Furthermore, we accepted only primary research articles which were available as full-text, but checked review articles for additional primary references.

We excluded studies using non-dynamic MRI methods, DSC-MRI or non-MRI methods in order to decrease variability between studies, which is already considerable between DCE-MRI studies. The literature search yielded several papers that focused on therapeutic BBB disruption for novel anti-cancer drugs. Since these mainly addressed pharmaceutical or technical aspects of the disruption method on a molecular level, these studies were rejected. An excellent review on DCE-MRI in clinical trials of antivascular therapies can be found in [@bb0065]. However, we did include studies that focused on the clinical effect of treatment strategies and its link with BBB disruption if they provided baseline DCE-MRI parameters. Moreover, we rejected single case reports and articles in which substantial information about the MRI procedure or the data analysis was lacking.

3.3. Data extraction and analysis {#sec3.3}
---------------------------------

One reviewer independently extracted the data from each included study and cross-checked information with preliminary extracted data. Disagreements were resolved by consensus. We noted the studied disease or pathology, sample size and subjects\' ages (in the case of human studies). Moreover, we extracted details of the DCE-MRI protocol, noting scanner field strength, MRI sequence with repetition time (TR) and echo delay time (TE), field of view, matrix size, slice thickness, overall duration and temporal resolution. Extracted data also included the type and dose of contrast agent and the injection protocol. Furthermore, we noted whether post-processing techniques were applied prior to data analysis, the analysis method used and the tissues/locations analyzed. Where given, quantitative measurements were extracted. We noted the main study purpose and the overall conclusion of the study.

In consequence of the large heterogeneity of included studies, quality assessment using standardized criteria as recommended in [@bb0032]) was difficult. However, we extracted limitations of the methodology where stated and whether any patients had been imaged but then excluded from further analysis, so as to assess the feasibility and applicability of the technique.

4. Results {#sec4}
==========

4.1. Systematic literature search results {#sec4.1}
-----------------------------------------

The electronic search yielded 829 results, 31 of which were in non-English languages. After removing duplicates, 352 publications were further analyzed for inclusion (see [Fig. 4](#f0020){ref-type="fig"}). After scanning abstracts and titles, we excluded studies using non-dynamic and non-MRI methods (*n* = 179). We also excluded review papers (*n* = 46), technical protocols (*n* = 2) and DSC-MRI studies (*n* = 38), leaving 87 articles for full-text assessment. At this stage, we identified 29 studies that were not relevant to the focus of this review. Moreover, we excluded conference abstracts that were not detailed enough for full data extraction and that had not subsequently been published in full (*n* = 8), single-case reports and publications with missing information on the imaging methodology (*n* = 2) and duplicate publications (*n* = 1). In addition to the resulting 47 relevant DCE-MRI studies, 23 relevant articles were identified by hand searching the bibliographies of review papers. Overall, the full literature search to February 2014 provided 70 DCE-MRI studies that were eligible for inclusion in this review, published between February 1990 ([@bb0045]) and December 2013 ([@bb0021]).

4.2. Subjects and sample sizes {#sec4.2}
------------------------------

[Table 1](#t0005){ref-type="table"} summarizes the main study sample characteristics and scanning protocols related to each pathology. Of the 70 included studies, 17 used animals (i.e. rodents ([@bb0014]; [@bb002]; [@bb004]; [@bb0024]; [@bb0026]; [@bb0028]; [@bb0063]; [@bb0084]; [@bb0037]; [@bb0046]; [@bb004]; [@bb0064]; [@bb0069]; [@bb007]; [@bb0011]), apart from one study of beagle dogs ([@bb0083]) and one of rabbits ([@bb0097])). The sample size was not made available in one of these publications ([@bb0026]). The mean sample size of the remaining animal studies was 25 animals, with a total number of 417 animals (including 19 healthy controls; 336/417 were rodents). The largest included study involved 113 rats ([@bb002]), whereas two studies used a sample size smaller than ten ([@bb0028]; [@bb004]).

The remaining 53 studies were in humans, including 1564 subjects in total (163 of which were healthy controls). The mean sample size for human studies was 27. Only one study involved more than 100 subjects ([@bb0033]) and six studies were based on fewer than ten humans ([@bb0041]; [@bb0049]; [@bb0045]; [@bb0087]).

Information regarding patient age was not provided in seven of the 53 studies ([@bb0055]; [@bb0054]; [@bb0077]; [@bb0049]; [@bb003]; [@bb0062]; [@bb008]). A further seven publications stated only the age range of the study subjects ([@bb008]; [@bb0034]; [@bb0070]; [@bb0093]; [@bb009]; [@bb0043]; [@bb0060]). Mean age as stated in the remaining 39 human studies was highly dependent on the studied pathology, ranging between 9 years ([@bb0087]) (pediatric brain tumors) and 74 years ([@bb0094]) (mild cognitive impairment).

4.3. Pathologies studied {#sec4.3}
------------------------

The majority of animal studies concerned intracranial neoplasms ([@bb0014]; [@bb004]; [@bb0028]; [@bb0037]; [@bb0046]; [@bb004]; [@bb0069]; [@bb007]) including a total of 140/417 animals. Five publications investigated changes in the BBB caused by induced focal cerebral ischemia in 154/417 animals overall ([@bb002]; [@bb0024]; [@bb0026]; [@bb0063]; [@bb0084]). Moreover, one study each focused on the influence of pneumococcal meningitis ([@bb0011]), normal aging ([@bb0083]), zinc deficiency ([@bb0064]) or traumatic head injuries ([@bb0097]) on the BBB.

The pathology most studied in humans was intracranial neoplasms (30 publications, 716/1564 subjects), including primary brain tumors and brain metastases ([@bb0054]; [@bb0077]; [@bb0050]; [@bb0049]; [@bb0033; @bb0035]; [@bb0087]; [@bb0062]; [@bb008]; [@bb0070]; [@bb009]; [@bb0060]; [@bb0016]; [@bb0017]; [@bb0019]; [@bb0036]; [@bb0059]; [@bb0058]; [@bb0057]; [@bb0061]; [@bb0068]; [@bb00102]; [@bb0027]; [@bb0042]; [@bb0047]; [@bb0099]; [@bb00101]. Eleven studies investigated changes in BBB integrity caused by stroke and/or cerebrovascular disease ([@bb0044]; [@bb0096]; [@bb0095]; [@bb0091]; [@bb006]; [@bb003]; [@bb0093]; [@bb0043]; [@bb0088]; [@bb0085; @bb0086]) with a total of 482/1564 subjects. Eight studies focused on multiple sclerosis ([@bb0041]; [@bb0049]; [@bb0045]; [@bb0021]; [@bb0086]; [@bb0029]; [@bb0074]; [@bb0039]) including a total of 186/1564 subjects. Other pathologies included Alzheimer\'s disease ([@bb0081]), mild cognitive impairment ([@bb0094]), brain tuberculomas ([@bb0075]; [@bb0034]), infective brain lesions ([@bb0033]), multiple system atrophy ([@bb0076]), diabetes ([@bb0082]) and neurocysticercosis ([@bb0031]).

4.4. Blood--brain barrier changes in disease {#sec4.4}
--------------------------------------------

Thirteen of the 70 included studies aimed to investigate the correlation between a particular disease and BBB dysfunction. For this purpose, BBB disruption was quantified in order to test for a significant difference between diseased subjects and healthy controls. Significant differences compared to control subjects or healthy tissue were found in eight studies, investigating acute ischemic stroke ([@bb002]), pneumococcal meningitis ([@bb0011]), brain metastases ([@bb0014]), multiple system atrophy ([@bb0076]), type-II diabetes ([@bb0082]), vascular cognitive impairment ([@bb0085]), normal-appearing and lesion tissue in multiple sclerosis patients ([@bb0021]; [@bb0086]), mild cognitive impairment ([@bb0086]), zinc deficiency ([@bb0064]) and small vessel disease ([@bb0091]). Moreover, Starr et al. observed differences in signal intensity profiles over time between Alzheimer\'s disease patients and controls ([@bb0081]). Increased BBB disruption without statistical significance was observed in patients with mild cognitive impairment ([@bb0094]). Su et al. showed a non-significant increase in BBB permeability with normal aging in beagle dogs ([@bb0083]).

16 studies performed DCE-MRI in order to distinguish between different types or grades of pathology. Seven of those studies showed statistical significance that DCE-MRI derived parameters differentiate primary brain tumor types and grades ([@bb0070]; [@bb0059]; [@bb0057]; [@bb0061]; [@bb00102]; [@bb0042]; [@bb00101]). Furthermore, significant differences were found between infective vs. neoplastic brain lesions ([@bb0033]), asymptomatic vs. symptomatic neurocysticercosis ([@bb0031]), severe and moderate vs. mild traumatic brain injuries ([@bb0097]), and radiation necrosis vs. tumor recurrence ([@bb0047]). Wardlaw et al. showed that post-contrast signal enhancement was higher in cerebrospinal fluid and white matter in lacunar (i.e. small vessel disease stroke) than in cortical (i.e. large artery atherothromboembolic stroke) patients ([@bb0096]; [@bb0095]). Kassner et al. found significantly different permeability scores between stroke patients who proceeded to hemorrhage and those who did not with and without thrombolytic therapy ([@bb0044]; [@bb0043]). Furthermore, [@bb003] reported significantly different DCE-MRI parameters for hemorrhagic strokes depending on their size and location.

4.5. Contrast agent and dose {#sec4.5}
----------------------------

The type and dose of contrast agents used in the included publications are summarized in [Fig. 5](#f0025){ref-type="fig"}. In most studies, the contrast agent used was Gd-DTPA (gadopentetate dimeglumine, 45/70 studies) or its variant Gd-DTPA-BMA (gadodiamide, 15/70 studies), given as an intravenous bolus injection. In 31 studies, this contrast agent was given in the standard dose of 0.1 mmol/kg body weight. However, delivered doses ranged from 0.02 mmol/kg ([@bb008]) to 0.5 mmol/kg ([@bb0028]). Ten studies delivered a fixed quantity of contrast agent, ranging between 7.5 mmol ([@bb0044]; [@bb0093]; [@bb0088]) and 20 mmol ([@bb0096]; [@bb0095]; [@bb006]) in humans. Single studies employed different gadolinium-based agents such as Gd-DOTA (gadoterate meglumine) ([@bb0055]; [@bb0019]), gadobutrol (Gd-BT-DO3A) ([@bb0041]; [@bb0021]; [@bb0099]; [@bb0039]; [@bb0076]; [@bb0048]), gadoteriol ([@bb0087]) and albumin-labeled Gd-DTPA ([@bb004]). We did not find any study that investigated the influence of different contrast agent types or concentrations, though Abo-Ramadan et al. state that different doses lead to an increase or decrease in signal-to-noise ratio ([@bb002]).

4.6. Scanning techniques and field strength {#sec4.6}
-------------------------------------------

The MRI pulse sequence types used are summarized in [Fig. 5](#f0025){ref-type="fig"}. The technique most frequently used was a spoiled gradient echo sequence (27 studies) and its ultra-fast variants (18 studies). Further protocols include 11 other gradient recalled echo sequences ([@bb0044]; [@bb0050]; [@bb0014]; [@bb002]; [@bb0024]; [@bb0037]; [@bb0069]; [@bb0043]; [@bb0016]; [@bb0088]; [@bb0048]), six spin-echo methods ([@bb0049]; [@bb0045]; [@bb0084]; [@bb0046]; [@bb0064]; [@bb0083]) and two unspecified T1-weighted imaging sequences ([@bb0082]; [@bb0076]). Furthermore, two studies used a TOMROP (T-One by Multiple Read-Out Pulses) pulse sequence ([@bb0026]; [@bb0063]), two studies used T1 mapping of partial inversion recovery (TAPIR) ([@bb0085; @bb0086]), and one study each used a THRIVE ([@bb0097]), RF-FAST ([@bb0094]) and TWIST ([@bb0042]) sequence.

Four publications focused on introducing new scanning methods. A scanning procedure for combined and consecutive DSC- and DCE-MRI measurement was introduced by [@bb0062] and [@bb0087] respectively. Moreover, [@bb0041] and [@bb0054] presented a dual-temporal resolution scanning method with high temporal resolution during the bolus first pass and high spatial resolution during the later phase.

The majority of human studies (35/53) were performed with a magnetic field strength of 1.5 T, while 16 studies used a 3 T scanner; one study each was performed using a 0.5 T ([@bb0045]) and a 1.9 T scanner ([@bb0082]). A wider range of magnetic field strengths from 1.5 T ([@bb0046]) to 11.75 T ([@bb004]) were found in animal studies, with the majority of studies using 4.7 or 7 T scanners. Two studies did not provide this information ([@bb0054]; [@bb0097]).

4.7. Duration and temporal resolution of DCE-MRI {#sec4.7}
------------------------------------------------

The duration of data collection following contrast injection varied widely with values from 2.1 min ([@bb0062] to 155 min ([@bb0074]). The median DCE-MRI imaging durations (not stated in five publications ([@bb0049]; [@bb004]; [@bb0011]; [@bb0019]; [@bb0068])) according to pathology studied are shown in [Table 1](#t0005){ref-type="table"}, together with the median temporal resolution (not stated in three publications ([@bb0011]; [@bb0019]; [@bb0068])). The highest temporal resolution of 1 s was found in tumor studies ([@bb0050]; [@bb0069]), whereas one study on diabetes used the longest intervals, in the range of 10--30 min ([@bb0082]).

[@bb0093] and [@bb0048] investigated the influence of the temporal resolution and/or overall scan time on the quantification of BBB disruption, finding that reducing the overall scanning time and sampling with a lower temporal resolution result in increased uncertainty of the pharmacokinetic parameters *K*^Trans^, *v~e~* and *v~p~*. As shown in [Table 1](#t0005){ref-type="table"}, the overall scanning duration and the temporal resolution vary significantly between applications. In general, the highest temporal resolution is used in brain tumors. This is necessary to measure the fast kinetics typically seen in malignant neoplasms, but may limit spatial resolution and coverage. Conversely, studies that assess tissues with slow leakage rates (e.g. healthy appearing tissue in MS patients, aging or dementia) often use lower temporal resolutions that allow for better spatial resolution and coverage.

4.8. Use of post-processing techniques {#sec4.8}
--------------------------------------

42 of the 70 included studies (60%) did not report the use or method of image post-processing. The most commonly used technique reported was image registration, aligning the DCE-MRI images to a pre-contrast acquisition and/or anatomic images, in order to remove patient movement ([@bb0041]; [@bb0044]; [@bb0096]; [@bb0095]; [@bb0082]; [@bb0081]; [@bb0091]; [@bb0014]; [@bb006]; [@bb0084]; [@bb0033; @bb0034],c; [@bb003]; [@bb0058]; [@bb00102]; [@bb0027]; [@bb00101]; [@bb0088]; [@bb0085]; [@bb0029]; [@bb0074]; [@bb0048]. Several studies reported a lack of precision of quantitative values due to limited spatial resolution or poor signal-to-noise ratio ([@bb0044]; [@bb0028]; [@bb0017]; [@bb0029]), but only four studies report the use of image processing techniques for noise reduction, including Gaussian smoothing ([@bb0058]), Kalman filtering ([@bb0085; @bb0086]) and unspecified smoothing of the signal enhancement curves ([@bb0027]). In addition, three studies corrected DCE-MRI data for scanner signal intensity drift using phantoms. Only one study investigated the effect of scanner noise and drift on signal enhancement data ([@bb006]), concluding that studies should investigate and if necessary correct for these influences in order to prevent systematic errors.

4.9. Data analysis methods and pharmacokinetic models {#sec4.9}
-----------------------------------------------------

A wide variety of approaches to data analysis were used in the included studies ([Fig. 6](#f0030){ref-type="fig"}). Model-free methods included the visual assessment of spatiotemporal enhancement patterns in multiple sclerosis lesions ([@bb0045]; [@bb0029]; [@bb0074]), calculation of semi-quantitative parameters from the signal enhancement ([@bb0096]; [@bb0095]; [@bb0082]; [@bb0081]; [@bb0091]; [@bb0011]; [@bb0083]; [@bb0062]; [@bb0094]; [@bb0061]; [@bb0068]; [@bb0099] and/or contrast agent concentration ([@bb0014]; [@bb006]) curves, and model-free deconvolution ([@bb0075]; [@bb0050]; [@bb0021]; [@bb0033; @bb0035]; [@bb008]; [@bb0027]; [@bb0047]; [@bb0031]). The most commonly used pharmacokinetic models were the conventional Tofts model ([@bb0075]; [@bb0041]; [@bb0055]; [@bb0064]; [@bb0033; @bb0034; @bb0035]; [@bb0087]; [@bb0060]; [@bb0017]; [@bb0036]; [@bb00102]; [@bb0027]; [@bb0042]; [@bb0031], the modified Tofts model ([@bb0054]; [@bb004]; [@bb0037]; [@bb007]; [@bb0097]; [@bb008]; [@bb009]; [@bb0016]; [@bb0019]; [@bb0036]; [@bb00101]; [@bb0039]; [@bb0076]; [@bb0048]), the Patlak model ([@bb0050]; [@bb0021]; [@bb002]; [@bb0024]; [@bb0026]; [@bb0063]; [@bb0084]; [@bb0046]; [@bb0093]; [@bb009]; [@bb0047]; [@bb0088]; [@bb0085; @bb0086]) and a simplified approach based on the Patlak model ([@bb0044]; [@bb0028]; [@bb003]; [@bb0070]; [@bb0043]) as introduced by [@bb0073] and [@bb0038]. Other modeling approaches included a variant of the conventional Tofts model that considers only the first pass of the contrast bolus ([@bb0055]; [@bb0036]), a two-compartment exchange ([@bb0077]; [@bb0050]) and uptake ([@bb0077]; [@bb0039]) model, and a modified two-compartment exchange model that includes two EES compartments (one in slow and one in fast exchange with the blood compartment) ([@bb0059]; [@bb0058]; [@bb0057]). Furthermore, one study each applied an AIF-free reference region model introduced by [@bb00100] in rat gliomas ([@bb0069]) and a shutter-speed model considering three-site equilibrium water exchange ([@bb004]). [Table 2](#t0010){ref-type="table"} summarizes the range of *K*^Trans^ estimates for different tissue types and pharmacokinetic models as reported in the included publications.

Several studies aimed primarily at comparing different approaches for data analysis. [@bb0055]) introduced a variant of the conventional Tofts model that only considers the first pass of the contrast bolus. They evaluated this method in *n* = 11 patients with primary brain neoplasms, finding that the results were visually comparable with those of the conventional Tofts model but less noisy and less susceptible to large vessel contributions. [@bb0036] evaluated the same model in *n* = 18 patients with high-grade gliomas, reporting a good correlation with the modified Tofts model but no correlation with the conventional Tofts method, though it should be noted that the AIFs used differed between the models due to software limitations. Values obtained with the conventional Tofts model were considerably higher, indicating an overestimation of quantitative parameters due to vessel contributions. [@bb0050] used simulated data in order to investigate the accuracy of the two-compartment exchange and Patlak models. As expected, they found that the Patlak method is accurate for low values of *K*^Trans^, whereas the two-compartment exchange model provides more accurate results for high *K*^Trans^ values ([@bb0050]). [@bb0056]) considered the effect of water exchange, finding the Patlak model to significantly underestimate the fractional blood volume when compared to their three-site equilibrium shutter-speed model. A non-parametric method for evaluating DCE-MRI in *n* = 16 glioma patients was presented by [@bb0027]), who showed that their resulting parameters closely approximate the conventional Tofts model parameters. Finally, [@bb009] presented a method for quantifying BBB disruption in heterogeneous glioblastoma based on a voxel-by-voxel selection from a set of nested models: the most complex model with three parameters was required to fit the data in regions of aggressive tumor growth, while simpler models predominated in less aggressive tumor portions and in healthy tissues.

5. Discussion {#sec5}
=============

Our systematic review of the literature revealed 70 studies involving methods to assess BBB disruption in 15 pathologies in 417 animals and 1564 humans. These studies showed considerable heterogeneity with regard to image acquisition and analysis methods. This is partly a consequence of the wide range of tissues, pathologies and study objectives. For example, tumor studies used higher temporal resolution and shorter imaging duration on average compared with studies of less permeable tissue such as multiple sclerosis, ischemic stroke and normal appearing brain. However, it should be noted that a minority of the articles explicitly justified the methodology used. The factors influencing inter-study comparability and implications for futures studies are discussed in the following paragraphs.

5.1. Inter-study comparability of quantitative DCE-MRI parameters {#sec5.1}
-----------------------------------------------------------------

Due to the wide range of analysis techniques used and their strong dependence on underlying assumptions and acquisition parameters, a lack of inter-study comparability represents a major problem. Care must be taken when comparing results from different studies as shown by the wide parameter ranges in [Table 2](#t0010){ref-type="table"}. Some of this variability is inevitable due to the heterogeneity of the study populations (e.g. subjects\' age) and study designs. Since most articles did not explicitly justify the analytical method employed, differences in the choice of pharmacokinetic model may account for some of the variation. Biased parameter estimates are likely to be obtained when the assumptions of the model are not met in the tissue or when the data acquired are inadequate to determine a unique solution. For example, several studies (e.g. [@bb004], [@bb00101]) apply the same model to tumor tissue and contralateral healthy tissue, although the underlying tissue physiology is very different and one model is unlikely to be valid in both situations. The importance of appropriate model selection has been demonstrated both theoretically ([@bb0079]) and experimentally in gliomas ([@bb0036]) and low-permeability brain tissue ([@bb0050]; [@bb0020]) and is discussed further in [Section 5.2](#sec5.2){ref-type="sec"}. Several additional factors may also influence the results of DCE-MRI studies.

Firstly, the calculation of contrast agent concentration from signal enhancement requires reliable estimation of intrinsic tissue parameters such as the pre-contrast longitudinal relaxation time T1~0~. There are several methods of estimating T1~0~, with variable flip angle ([@bb0013]) and variable saturation time delay ([@bb0051]) being the most common. The effect of uncertainty in T1~0~ estimation on the calculation of contrast agent concentrations has been investigated by Schabel and Parker ([@bb0072]). They demonstrate that T1~0~ produces a significant concentration bias, which shows the importance of accounting for T1~0~ when assessing BBB disruption in different tissue types ([@bb006]). It should also be noted that, unless T1 is measured at each time point, drifts in signal intensity may introduce further errors in pharmacokinetic parameters; as noted above, the issue of scanner stability was seldom addressed in the included articles.

Secondly, most pharmacokinetic models require the AIF to be known. Hence, determination of AIF represents a key issue in the reliable estimation of pharmacokinetic parameters. As mentioned above, there are several strategies for AIF selection and the optimal method varies according to pathology, study aims and clinical requirements ([@bb0015]). In most applications, direct measurement of the AIF is generally considered preferable to standard or averaged AIFs ([@bb0052]). However, this method is not always possible and is susceptible to partial volume and in-flow artefacts; uncertainty remains regarding which vessel should be sampled and how, with approaches ranging from manual region of interest selection to methods for automatic vessel detection ([@bb0018]). There is also disagreement on whether to describe the capillary bed in terms of blood concentration or plasma concentration by correcting for the hematocrit (Hct). In the latter case, Hct should ideally be determined for every subject, but a standard value such as Hct = 0.45 is often assumed ([@bb0078]). In theory, all model equations and resulting parameter values can easily be converted between conventions. However, several studies did not report this and other details, impeding reliable comparison of parameter values from different studies.

Other sources of uncertainty rarely considered in DCE-MRI studies may arise due to a lack of available data. For example, relaxivity values specific to a contrast agent, field strength and tissue/pathology are rarely known, with the consequence that uniform relaxivity across tissues and compartments is generally assumed. A further common assumption is that of fast water exchange between compartments; the influence of restricted water exchange has been described in the literature (see 100 and references therein) but models accounting for this effect have received relatively little attention.

5.2. Implications for future DCE-MRI studies of BBB disruption {#sec5.2}
--------------------------------------------------------------

Given the diversity of DCE-MRI applications in the brain, it is impossible to prescribe a universal "recipe" for future studies, though attempts have been made to better standardize methodology and reporting ([@bb0089]; [@bb0022]; [@bb0053]). Instead, it is essential to recognise that the optimal method is highly dependent on the specific application. An extensive body of primary DCE-MRI literature and a number of excellent review articles should help to facilitate optimal study design in the future. In the following paragraphs we discuss some of the key aspects of acquisition protocol design and data analysis. In addition to these technical aspects, it should be noted that the overall design of a study (e.g. large sample size, appropriate control group) will be particularly important given the limitations of present DCE-MRI methods. We recommend that for most applications, changes in the longitudinal relaxation rate rather than signal intensity should be measured, since the former more accurately reflects contrast agent concentration, required for quantitative pharmacokinetic analysis. A range of pulse sequences are available to obtain this data, and the optimal choice may be a compromise between speed, accuracy, spatial coverage and other factors. Two of the most critical acquisition parameters to determine are the temporal resolution and total duration of the scan, since the optimal values depend on the nature of the tissue being investigated and the quantities to be measured ([@bb0080]). For example, temporal resolution of the order of a second is required to quantify tissue plasma flow; even if this quantity is of no interest, it may be necessary to account for flow in order to accurately assess permeability. The likely influence of blood flow may be determined using computer simulations, providing plausible tissue parameter ranges are available and relevant to the subjects and tissues being studied ([@bb0077]; [@bb0050]). Temporal resolution must also be set against requirements for *spatial* resolution and coverage, which differ markedly between applications (e.g. focal vs. diffuse pathology). For accurate measurement of the permeability-surface area product *PS*, the scan duration should be long enough for significant contrast extravasation to occur: this may be on the order of a few minutes in tissues such as brain tumors, but longer scans are required in less permeable tissues such as normal-appearing brain. If the EES volume fraction *v*~e~ is to be accurately measured then imaging should continue well into the "washout" phase, when the EES contrast agent concentration begins to fall. Further research is needed to investigate how variations in contrast agent types and doses affect pharmacokinetic parameters.

A wide range of pharmacokinetic models have been proposed for fitting DCE-MRI data, the most popular of which divide the tissue into well-mixed compartments. It is essential to recognize the assumptions built into these models and to assess their likely validity for a given application ([@bb0078]). The original Tofts model, for example, is strictly valid only in weakly vascularized tissues, where contrast agent in the capillaries can be neglected; furthermore, the fitted *K*^Trans^ is equal to *PS* only when the blood flow is sufficiently high. For tissues where the vascular contribution is significant, the Patlak or extended Tofts models may be more appropriate, provided again that plasma flow is high. The choice of model should also reflect the MRI protocol: if the acquisition duration is short and BBB leakage is slow then models that do not allow back-diffusion (e.g. Patlak and tissue-uptake models) may be suitable, while application of a model that does include back-diffusion (e.g. extended Tofts model) can result in increased uncertainty in the fitted parameters. Similarly, application of a model that includes flow (e.g. tissue-uptake and two-compartment exchange models) is counterproductive if the acquired temporal resolution is insufficient. These and other considerations have been investigated theoretically by [@bb0079] and are summarized accessibly in their recent review ([@bb0078]). A recent investigation by Cramer et al. further emphasized the importance of appropriate model selection in the context of subtle BBB permeability ([@bb0020]). If it is unclear which model to select *a-priori* then data-driven approaches, e.g. use of Akaike information criteria, can be used to determine the most suitable model ([@bb0025]), although this does not guarantee that the model assumptions are met.

As most current data apply to tumors, more data are required for assessing low-level BBB abnormalities. The relative lack of methodological assessments to determine the best methods of measuring low level BBB disruption in normal or abnormal appearing brain in aging, dementia or brain microvascular disease, argue for substantially more work to determine the optimum contrast and dose, acquisition parameters, and data analysis methods.

6. Conclusion {#sec6}
=============

This systematic review has highlighted the wide range of applications where DCE-MRI has been used to assess BBB integrity. We found large variations in studied pathologies, MRI procedures and data analysis methods resulting in widely varying estimates of permeability parameters. Nevertheless, DCE-MRI has been shown to provide valuable information in a growing field of applications, ranging from the grading of primary brain tumors to the assessment of healthy-appearing tissue in multiple sclerosis patients or dementia. In methodological terms, DCE-MRI is a relatively mature technique, but the lack of agreed standards for image acquisition, data modeling and study reporting hinders inter-study comparison and meta-analysis. Improved reliability of DCE-MRI, especially in subtle permeability states, is required. Where feasible, further technical development should be accompanied by attempts to establish consensus-based recommendations for data acquisition and analysis in order to improve inter-study comparability and promote wider use of DCE-MRI both clinically and in research ([@bb0089]; [@bb0022]; [@bb0053]).
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![Schematic drawing of the neurovascular unit. The BBB is formed by endothelial cells that line brain capillaries and are sealed by tight junctions. Astrocytes, pericytes, microglial cells and basement membranes interact with the endothelium of the BBB, providing functional and structural support.](gr1){#f0005}

![Illustration of DCE-MRI in a patient with a glioma. The repeated acquisition of T1-weighted images after contrast agent injection allows the calculation of signal enhancement as a function of time (middle) when compared to the pre-contrast signal intensity (left). These curves can be used to calculate maps of quantitative pharmacokinetic parameters (e.g. *K*^Trans^, right).](gr2){#f0010}

![Schematic illustrations of common pharmacokinetic models and target parameters. The exchange between the extravascular extracellular space (EES, volume fraction *v~e~*) and capillary blood plasma (volume fraction *v~p~*) is determined by the plasma flow *F~p~* and the permeability-surface area product *PS.* (A) Generic tissue model. (B) Conventional Tofts model (with negligible blood volume and volume transfer constant *K*^Trans^). (C) Modified Tofts model with non-negligible blood compartment. (D) Patlak model with non-negligible plasma compartment and one-way transport of contrast agent across the BBB. For the latter two models, it may be assumed that *K*^Trans^ = *PS* for any solution fitting the data well with a non-negligible *v*~p~.](gr3){#f0015}

![Flow diagram summarizing the literature search and inclusion process.](gr4){#f0020}

![Summary of contrast agents, contrast agent doses and MRI sequences. The bar height indicates the number of studies using a particular method, subdivided by pathology.](gr5){#f0025}

![Data analysis methods used in the included studies. Numbers indicate the count of studies using the particular method. (Note that some studies used more than one approach. Consequently, the numbers of studies do not add up to the 70 included studies.).](gr6){#f0030}

###### 

Study sample characteristics and scanning protocols related to pathology. 'Mean age' displays the average of study mean ages for studies investigating the same pathology.

  Pathology                          Sample    Scanning protocol   References                                                                                                        
  ---------------------------------- --------- ------------------- ------------ ------ ------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intracranial neoplasms             Humans    30                  716          48.4   5.5     5.3                                                                                   [@bb0075]; [@bb0055]; [@bb0054]; [@bb0077]; [@bb0050]; [@bb0049]; [@bb0033; @bb0035]; [@bb0087]; [@bb0062]; [@bb008]; [@bb0070]; [@bb009]; [@bb0060]; [@bb0016]; [@bb0017]; [@bb0019]; [@bb0036]; [@bb0059]; [@bb0058]; [@bb0057]; [@bb0061]; [@bb0068]; [@bb00102]; [@bb0027]; [@bb0042]; [@bb0047]; [@bb0099]; [@bb00101]; [@bb0048]
  Animals                            8         140                 −            15.0   11.5    [@bb0014]; [@bb004]; [@bb0028]; [@bb0037]; [@bb0046]; [@bb004]; [@bb0069]; [@bb007]   
  Stroke / cerebrovascular disease   Humans    11                  482          65.9   9.0     14.0                                                                                  [@bb0044]; [@bb0096]; [@bb0095]; [@bb0091]; [@bb006]; [@bb003]; [@bb0093]; [@bb0043]; [@bb0088]; [@bb0085; @bb0086]
  Animals                            5         154                 −            25.0   150.0   [@bb002]; [@bb0024]; [@bb0026]; [@bb0063]; [@bb0084]                                  
  Multiple sclerosis                 Humans    8                   186          41.3   21.8    34.8                                                                                  [@bb0041]; [@bb0049]; [@bb0045]; [@bb0021]; [@bb0086]; [@bb0029]; [@bb0074]; [@bb0039]
  Pneumococcal meningitis            Animals   1                   42           −      n/a     n/a                                                                                   [@bb0011]
  Zinc deficiency                    Animals   1                   36           −      36.0    240.0                                                                                 [@bb0064]
  Neurocysticercosis                 Humans    1                   35           n/a    3.0     5.7                                                                                   [@bb0031]
  Traumatic head injuries            Animals   1                   30           −      7.5     15.0                                                                                  [@bb0097]
  Alzheimer\'s disease               Humans    1                   30           73.7   34.4    229.0                                                                                 [@bb0081]
  Multiple system atrophy            Humans    1                   29           59.0   6.0     7.7                                                                                   [@bb0076]
  Infective brain lesions            Humans    1                   26           26.6   2.8     5.3                                                                                   [@bb0033]
  Mild cognitive impairment          Humans    1                   22           47.0   6.8     25.5                                                                                  [@bb0094]
  Diabetes                           Humans    1                   20           68.2   90.0    900.0                                                                                 [@bb0082]
  Brain tuberculomas                 Humans    2                   18           23.2   2.8     5.3                                                                                   [@bb0075]; [@bb0034]
  Normal aging                       Animals   1                   15           −      12.0    15.0                                                                                  [@bb0083]

###### 

*K*^Trans^ values reported for different tissue types and pharmacokinetic models. Given values are the median \[range\] of reported study sample means from human (in black) and animal (in orange) studies. Please note that some subjects included in these studies (e.g. high grade glioma patients) underwent treatment before entering the study. Hence, the reported baseline parameters might be influenced by interventions that were not the focus in the study.
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